Fig. 1
From: High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer
The pattern of IL4I expression in Pan-cancers and in thyroid cancer. A The mRNA expression of IL4I1 was upregulated in 28 of 33 cancers (*** p < 0.001), in KICH (** p < 0.01) and in PCPG (* p < 0.05) compared with normal tissues. B The mRNA expression in THCA from data of TCGA. C The mRNA expression in 3 THCA and the matched-adjacent normal samples. D The protein levels of IL4I1 from data of Human Protein Atlas. ns, no significance; BLCA, bladder urothelial carcinoma; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, Uterine Carcinosarcoma; UVM, Uveal Melanoma